Double Bond Pharmaceutical International AB (publ) (DBP-B.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.112 (-0.44%) as of
Key statistics
- Market cap
- 24.96M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0900 – 0.2680
- Beta
- 0.77
- Revenue (TTM)
- 274.15k
- Profit margin
- 122.43%
- Volume
- 285.45k
About Double Bond Pharmaceutical International AB (publ)
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of cancers and infectious diseases. It offers Temodex / SI053, a gel formulation of temozolomide for the local treatment of glioblastoma; SA-033, a novel treatment of cancers in liver; and SA-083 for the treatment of lung tumour. The company is also developing Belopenem for the treatment of bacterial pneumonia; and BeloGal, a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipients. Double Bond Pharmaceutical International AB (publ) was incorporated in 2014 and is based in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Uppsala, Sweden
- Employees
- 8
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.